PPD signs exclusive agreement with China-based AI company

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Rainer Puster)
(Image: Getty/Rainer Puster)

Related tags: China, AI, technological, Patient recruitment, RWE, RWD, Clinical research

PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.

The agreement, announced yesterday, brings together HLT’s data and artificial intelligence (AI) technology with PPD’s clinical trials and real-world evidence (RWE) generation abilities.

“The collaboration with HLT provides a creative opportunity to encourage more pharma companies to come to China where we can help them create better optimized protocols that will prove more attractive to sites and investigators because they are tailored more to their patient population,”​ said Niklas Morton, senior vice president of site and patient access for PPD.

As part of the agreement, the contract research organization (CRO) will tap HLT’s network of more than 100 hospitals across 22 Chinese provinces.

Morton explained, “In China, HLT can leverage its large network of physicians and leading Chinese hospitals and has the most advanced analytical capabilities to assist with our strategy of identifying patients first.”

PPD last year launched​ a site solution for enrolling patients in clinical studies, proposing to enroll patients first – before activating sites – via a new enrollment model.

“Traditional clinical research has focused on using site-performance data to identify the strongest sites and investigators for new clinical trials,”​ Morton told us.

“PPD’s recent strategic focus has been on using data to first identify eligible patient populations and then seek the sites and investigators best positioned to access those patients.”

Morton also noted the company’s investment in data over the past five years, citing the agreement as fitting with PPD’s strategy to speed patient enrollment.

“Since we have an exclusive CRO collaboration with HLT that will give us a unique offering for our customers,”​ he added.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars